Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANGIODYNAMICS INCANGO · Entity 5275 | EVP and CFO | October 16, 2019 | October 18, 2019 |
| AVANOS MEDICAL, INC.AVNS · Entity 28189 | Former Interim CEO | May 13, 2025 | May 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANGIODYNAMICS INC
Report date October 16, 2019 · Filed October 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance RightSEC Table II · derivative / convertible security | Direct | 15,320 |
Reported balance
After 2019-10-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-16 · Grant · Acquired 15,320 · Balance 15,320 F1: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.
AVANOS MEDICAL, INC.
Report date May 13, 2025 · Filed May 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 200,019 |
Ending reported balance
After 2025-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-13 · Tax withholding · Disposed 19,771 · Balance 204,493 F1: Reflects shares surrendered to the Issuer to satisfy tax withholding obligations upon the vesting of 44,189 time-based restricted share units (TRSUs) which: (i) were awarded to the Reporting Person on October 29, 2024 and (ii) vested on May 13, 2025. Each TRSU is the economic equivalent of one share of Common Stock. Row 2 · 2025-05-13 · Tax withholding · Disposed 4,474 · Balance 200,019 F2: Reflects shares surrendered to the Issuer to satisfy tax withholding obligations upon the vesting of 10,000 time-based restricted share units (TRSUs) which: (i) were awarded to the Reporting Person on December 3, 2024 and (ii) vested on May 13, 2025. Each TRSU is the economic equivalent of one share of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares surrendered to the Issuer to satisfy tax withholding obligations upon the vesting of 44,189 time-based restricted share units (TRSUs) which: (i) were awarded to the Reporting Person on October 29, 2024 and (ii) vested on May 13, 2025. Each TRSU is the economic equivalent of one share of Common Stock.
F2: Reflects shares surrendered to the Issuer to satisfy tax withholding obligations upon the vesting of 10,000 time-based restricted share units (TRSUs) which: (i) were awarded to the Reporting Person on December 3, 2024 and (ii) vested on May 13, 2025. Each TRSU is the economic equivalent of one share of Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2017 Filed Jul 28, 2017 19:08 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 21,762 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0001140361-17-029083 · doc1.xml · derivative · entry 2 Greiner Michael · CIK 0001520392 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,762 Underlying: Common Stock · 21,762 shares Expires 2027-07-26 F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 26, 2018, such that 25% of the options will vest on each of July 26, 2018, 2019, 2020 and 2021. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 19:08 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 6,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-029083 · doc1.xml · nonDerivative · entry 1 Greiner Michael · CIK 0001520392 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,193 F1 · shares: This acquisition of 6,193 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,193 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 26, 2018, such that 25% of the restricted stock units will vest on each of July 26, 2018, 2019, 2020 and 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.